Michael Mezher is the Managing Editor at Regulatory Focus. He specializes in FDA regulations, drug approvals, and the pharmaceutical industry, with a keen interest in healthcare technology. Michael's insights and expertise are featured in the Regulatory Affairs Professionals Society (RAPS).
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Michael Mezher's coverage predominantly focuses on health, pharmaceuticals, and FDA-related topics. His articles often revolve around government announcements, legal policy regulations, and press releases within the healthcare sector.
Given his focus on FDA activities and pharmaceutical developments, Michael is likely to be interested in pitches related to new drug approvals or rejections by the FDA, significant clinical trial outcomes, updates on COVID-19 vaccines or treatments, as well as regulatory changes impacting the pharmaceutical industry.
Pitches that offer insights into how specific drugs or medical devices are faring in trials or navigating regulation could resonate with Michael's coverage interests. Experts familiar with FDA processes and implications for the healthcare industry may find their perspectives valuable for engaging him effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Michael Mezher
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
By: Michael Mezher
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
By: Michael Mezher
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
By: Michael Mezher
The US Food and Drug Administration (FDA) on Friday began the reauthorization process for the next iteration of the Generic Drug User Fee Amendments (GDUFA IV) with a public meeting to gather input from stakeholders ahead of negotiations with industry.
By: Michael Mezher
Regulatory professionals must navigate change and uncertainty amid an evolving global regulatory landscape, new technologies such as artificial intelligence (AI), and the rapid pace of scientific advancement. This year@s RAPS Convergence will feature insights from regulators and industry experts to help attendees stay ahead of the curve and deliver innovative healthcare products to patients.
By: Michael Mezher
Welcome to another installment of This Week at FDA, your weekly source for updates@big and small@on FDA, drug, and medical device regulation and what we@re reading from around the web. This week, FDA published two guidance documents despite the ongoing government shutdown, some FDA staff reported payroll issues, and the agency is reportedly considering another overhaul of its inspection program.
By: Michael Mezher
The healthcare product landscape in Europe is undergoing significant transformation—from multiple legislative overhauls to the rapid adoption of artificial intelligence (AI) and other boundary-pushing technologies. For regulatory professionals attending RAPS Euro Convergence 2026 in Lisbon, the meeting is an opportunity to lean into community to stay on top of the myriad changes coming their way.
By: Michael Mezher
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
